A randomized controlled trial to determin the efficacy of folic acid for lowering hyperhomocystinemia in hemodialysis patients and improving left ventricular hypertrophy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015116

Enrollment

Unknown

Registered

2018-03-08

Start date

2018-03-01

Completion date

Unknown

Last updated

2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis

Interventions

Experimental group:Oral Folic Acid Tablets 15 mg/d+ vitamin B6 60mg/d+ vitamin B12 tablet 0.5mg/d

Control group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Dialysis time> 3 months; dialysis twice a week for 4 hours, blood flow 200 ~ 250ml / min; dialysate flow 500ml / min, dialysate calcium concentration 1.25 ~ 1.5mmol / L;All patients were given drug eluting for 6 weeks, and stopped taking folic acid, vitamin B6 and vitamin B12 drugs.

Exclusion criteria

Exclusion criteria: 1. infection within 1 month prior to enrollment; 2. acute cardiovascular events within 1 month prior to enrollment; 3. use of hormones or immunosuppressive agents; 4. malignancy, mental illness, or pregnancy.

Design outcomes

Primary

Measure	Time frame
homocysteine;left ventricular hypertrophy;	—

Countries

China

Contacts

Public ContactMinjia LI

The Third Affiliated Hospital, Sun Yat-Sen University, Yuedong Hospital

xxef@163.com+86 17827381184

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026